Retrospective Case Reports of Anemic Pregnant Women Receiving Intravenous Ferric Carboxymaltose: Experience from a Tertiary Hospital in Spain

Table 1

Response to intravenous ferric carboxymaltose.

	(%)	Maternal age, years	Pregnancy week at time of first FCM treatment	Pre-treatment Hb, g/dL	Post-treatment Hb, g/dL^#
First trimester	4 (4.2%)	38 (34; 41)	11 (9; 14)	8.0 (7.7; 8.3)	11.6 (11.4; 11.7)
Second trimester	28 (29.5%)	31 (28; 36)	26 (24; 27)	8.6 (8.0; 8.8)	11.7 (11.3; 12.5)
Third trimester^†	63 (66.3%)	28 (23; 34)	35 (31; 38)	8.6 (8.1; 8.9)	10.2 (9.6; 11.0)
All	95 (100%)	30 (24; 35)	31 (27; 37)	8.5 (8.1; 8.9)	11.0 (9.9; 11.7)

Data shown as median (IQR) or (%).
Three women received at least one further treatment (two women received two FCM administrations and one woman received three FCM administrations).
^†One woman received two FCM administrations of 1000 mg iron three weeks apart.
^#Routine laboratory control was performed either between 7 and 14 days (women in third trimester of pregnancy) or between 20 and 40 days (women in first or second trimester of pregnancy) after treatment.
FCM, ferric carboxymaltose; Hb, hemoglobin; IQR, interquartile range.